Overview
- The Danish Patient Compensation Authority granted a total of 800,000 kroner (about €107,000) to four individuals who developed NAION after using semaglutide medicines Wegovy or Ozempic.
- The agency has processed five of more than 40 claims so far, rejecting one and approving four, with additional cases still under review.
- NAION is a rare ischemic optic‑nerve condition that can cause sudden, often permanent vision loss.
- The EMA’s risk committee classifies NAION as a very rare side effect of semaglutide and advises urgent evaluation for sudden vision changes, with treatment stopped if NAION is confirmed.
- Novo Nordisk has updated product information to include NAION as a very rare risk, and Danish officials say the medically complex cases could lead to higher payouts depending on long‑term impact.